


VIFOR PHARMA DIVESTMENT OF FINISHED DRUG PRODUCT MANUFACTURING BUSINESS

Posted on 1 February 2022



Category: [Pharma](#)

Tags: [Christine Bassanello](#), [Emanuel Dettwiler](#), [Ex-Featured](#), [Jon Oetiker](#), [Kellerhals Carrard](#), [Philipp d'Hondt](#), [Sophie Holdt](#)



Vifor Pharma Group closed its divestment transaction regarding its finished drug product manufacturing business with facilities in Fribourg, Ettingen (both in Switzerland) and Lisbon (Portugal) to CordenPharma, a full-service Contract Development & Manufacturing Organisation (CDMO) of APIs, Excipients, Drug Products, and associated Packaging services.

The Vifor Pharma Group is a global pharmaceutical company aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.

The companies have agreed not to disclose financial terms of the agreement.

[Kellerhals Carrard](#) acted as legal advisor to Vifor Pharma on this transaction. The team was led by partner **Emanuel Dettwiler** (pictured) and comprised senior associate **Sophie Holdt**, associate **Jon Oetiker** (all corporate/m&a), and counsels **Christine Bassanello** (employment) and **Philipp d'Hondt** (notarial services).